Velocity-Based Resistance Training Effects on Inflammation in Older Adults
maanantai 4. toukokuuta 2026 päivittänyt: National Taipei University
Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults.
Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group.
Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase.
The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
Tutkimuksen yleiskatsaus
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
60
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Shun-Hsi Tsai, Ph.D.
- Puhelinnumero: 68523 +88686741111
- Sähköposti: shunhsi@mail.ntpu.edu.tw
Opiskelupaikat
-
-
-
Taipei, Taiwan, 116
- Rekrytointi
- National Taiwan Normal University
-
Ottaa yhteyttä:
- Hung-Wen Liu, Ph.D.
- Puhelinnumero: +88677496863
- Sähköposti: hwliu@ntnu.edu.tw
-
Ottaa yhteyttä:
- Kuan-Tsen Yeh, M.S.
- Puhelinnumero: +886932815383
- Sähköposti: mickyyehyeh@gmail.com
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
Inclusion Criteria:
- Aged 60-75 years or older
- No regular resistance training habit (defined as ≥2 sessions per week) in the past year
- No musculoskeletal injuries within the past six months
Exclusion Criteria:
- Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
- Regular use of anti-inflammatory medications (e.g., NSAIDs).
- Smoking or alcohol abuse
- Inability to safely perform the prescribed resistance exercise movements
- Unable to fully comprehend the study information and instructions.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% from the first repetition.
Rest intervals of 2-3 minutes will be provided between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Kokeellinen: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Kokeellinen: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Ei väliintuloa: sedentary control
Participants in control trial stayed sedentary during the period.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Changes in IL-6 concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Plasma IL-6 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble IL-6 receptor concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble gp130 concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble gp130 concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-10 concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-10 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-1RA concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-1RA concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in TNF-α concentration
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
TNF-α concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Borgs Ratings of Perceived Exertion (RPE)
Aikaikkuna: 1-hour during each exercise intervention
|
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
|
1-hour during each exercise intervention
|
|
Handgrip strength
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Knee extension strength
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
30-second chair-stand test
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Single-leg balance test
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Timed up and go test
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in gp130 (CD130) protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in STAT3 protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in phosphorylated STAT3 protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SOCS3 protein expression in PBMCs
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in white blood cell count
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total white blood cell count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in lymphocyte count
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lymphocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in neutrophil count
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Neutrophil count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in monocyte count
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Monocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Body fat percentage
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Lean body mass
Aikaikkuna: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Shun-Hsi Tsai, Ph.D., National Taipei University
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 20. huhtikuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Torstai 1. maaliskuuta 2029
Opintojen valmistuminen (Arvioitu)
Lauantai 1. joulukuuta 2029
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Keskiviikko 15. huhtikuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 28. huhtikuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Tiistai 5. toukokuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Perjantai 8. toukokuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 4. toukokuuta 2026
Viimeksi vahvistettu
Keskiviikko 1. huhtikuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- ECKIRB1140803
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Tulehdusreaktio
-
Ankara Etlik City HospitalAktiivinen, ei rekrytointiPan Immune Inflammatory Indexin ja endometrioosin ja endometrioosin vaiheiden välinen suhdeTurkki